Management of CKD Stage 4

Immediate Actions and Referral

• The American Journal of Kidney Diseases recommends referring all CKD stage 4 patients to nephrology immediately, as this improves outcomes, reduces costs, and allows timely preparation for dialysis or transplantation 1, 2
• Patient education about renal replacement therapy options should begin as soon as stage 4 is reached, since progression rates are unpredictable and preparation takes months 2

Blood Pressure and Cardiovascular Management

Target Blood Pressure

• The American College of Cardiology recommends targeting systolic blood pressure <120 mmHg when tolerated using standardized office measurement 3
• Hypertension prevalence approaches 80% in stage 4 CKD and requires aggressive management 1

Renin-Angiotensin System Blockade

• The Kidney International Supplements guideline recommends starting ACE inhibitor or ARB as first-line therapy for blood pressure control and proteinuria reduction 4, 3
• Monitor serum creatinine and potassium within 2-4 weeks of initiation or dose increase 3
• Continue ACE inhibitor/ARB unless creatinine rises >30% within 4 weeks of starting therapy 3
• Never combine ACE inhibitor with ARB due to increased risk of hyperkalemia and acute kidney injury 3
• Manage hyperkalemia with dietary restriction and potassium binders rather than immediately discontinuing ACE inhibitor/ARB 3

Volume Management

• The Praxis Medical Insights guideline recommends using loop diuretics (not thiazides) for volume control in patients with fluid overload 3
• Restrict dietary sodium to <2g per day to enhance blood pressure control 3

Diabetes Management (if applicable)

• The Praxis Medical Insights guideline recommends starting SGLT2 inhibitor if patient has type 2 diabetes and eGFR ≥20 mL/min/1.73 m² 3, 5
• Continue SGLT2 inhibitor even if eGFR falls below 20 mL/min/1.73 m² unless not tolerated or dialysis initiated 5
• Use glipizide as preferred sulfonylurea due to lack of active metabolites 5
• Consider DPP-4 inhibitors (sitagliptin, saxagliptin, linagliptin) with appropriate dose adjustments 5
• Insulin requires careful dose adjustment due to reduced renal clearance 5

Slowing Disease Progression

• The Kidney International Supplements guideline recommends reducing proteinuria/albuminuria as a primary treatment goal using ACE inhibitors or ARBs 4
• Target reduction in urinary albumin excretion correlates directly with slowing CKD progression 4

Monitoring Complications

Mineral and Bone Disorder

• The Kidney International guideline recommends monitoring serum calcium and phosphorus every 3-6 months 6
• Monitor PTH every 6-12 months 6
• Measure alkaline phosphatase annually or more frequently if PTH elevated 6
• Measure 25(OH)D levels and correct deficiency using general population treatment strategies 6

Anemia

• The Kidney International guideline recommends performing complete blood count at least monthly after initial stabilization 6
• Assess and treat anemia by removing underlying causes and using standard CKD measures 6

Metabolic Monitoring

• The Praxis Medical Insights guideline recommends monitoring for hyperkalemia, metabolic acidosis, and electrolyte abnormalities regularly 5

Cardiovascular Risk

• The Kidney International Supplements guideline recommends monitoring for cardiovascular disease as CKD patients have markedly elevated cardiovascular mortality 4

Preparation for Renal Replacement Therapy

Timing and Education

• The American Journal of Kidney Diseases recommends beginning structured pre-dialysis education program when stage 4 is reached to allow time for decision-making and access creation 2
• Evaluate for preemptive kidney transplantation including living donor assessment 2
• Education should include patient, family members, and primary care providers 2

Vascular Access Planning

• The American Journal of Kidney Diseases recommends creating arteriovenous fistula in advance for patients likely to require hemodialysis, recognizing that success may take weeks to months 2
• For patients interested in peritoneal dialysis, delay AVF creation and focus on PD catheter planning 2

Medication Adjustments and Avoidance

• The Kidney International guideline recommends avoiding nephrotoxic agents including NSAIDs, COX-2 inhibitors, and contrast media 6
• Avoid allopurinol in patients receiving azathioprine 6

Indications for Urgent Intervention

• The Praxis Medical Insights guideline recommends referring urgently for uremic symptoms, BUN >100 mg/dL, or altered mental status 3, 7
• Consider dialysis initiation for refractory volume overload, severe hyperkalemia, uremic encephalopathy, pericarditis, or severe metabolic acidosis (pH <7.2) 7

Follow-up Schedule

• The Praxis Medical Insights guideline recommends checking serum creatinine, potassium, and blood pressure within 2-4 weeks of starting ACE inhibitor/ARB 3

Management of CKD Stage 4

Cardiovascular Risk Reduction

• The National Kidney Foundation recommends treating adults aged ≥50 years with a statin or statin/ezetimibe combination to reduce cardiovascular risk 8, 9, 10
• The American Heart Association suggests choosing statin-based regimens to maximize absolute reduction in LDL cholesterol 8, 9, 10
• The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines recommend considering PCSK-9 inhibitors for patients with CKD who have an indication for their use 8, 9, 10
• A plant-based "Mediterranean-style" diet may be considered in addition to lipid-modifying therapy to reduce cardiovascular risk 8, 9, 10
• The American College of Cardiology recommends using oral low-dose aspirin for secondary prevention in patients with established ischemic cardiovascular disease 8, 9, 10

Indications for Urgent Dialysis Initiation

• The European Renal Association - European Dialysis and Transplant Association (ERA-EDTA) recommends referring urgently for dialysis if severe hyperkalemia is unresponsive to medical management 9

Blood Pressure Management

• Hypertension prevalence approaches 80% in Stage 4 CKD and requires aggressive management, according to the American Journal of Kidney Diseases 11

Management of CKD Stage IV Patients Awaiting Kidney Transplantation

Immediate Nephrology Engagement

• Active nephrology follow‑up at the time of transplant listing improves clinical outcomes, reduces health‑care costs, and enables timely preparation for transplantation or bridge dialysis if needed (KDIGO recommendation, moderate evidence) 12.

Pre‑Transplant Education & Living‑Donor Evaluation

• Structured education for patients and families about the transplant evaluation process, post‑transplant care, and the possibility of needing bridge dialysis should be initiated promptly (KDIGO) 12.
• Early systematic assessment for a living‑donor kidney is advised, as living‑donor transplantation provides superior graft survival and may permit pre‑emptive transplantation (KDIGO) 13.

Vascular Access Planning

• Create an arteriovenous fistula when the expected time to transplantation exceeds 6–12 months, because fistula maturation requires several weeks to months and ensures reliable access if dialysis becomes necessary (KDIGO) 12, 13.
• Do not delay vascular‑access creation; postponement can leave the patient without adequate access should urgent dialysis be required (KDIGO) 12, 13.

Monitoring for Urgent Dialysis Indications

• Closely monitor for uremic complications that mandate emergent dialysis, including encephalopathy, pericarditis, refractory fluid overload, severe hyperkalemia (>6.5 mmol/L), severe metabolic acidosis (pH < 7.2), or BUN > 100 mg/dL with altered mental status (KDIGO) 14, 13.
• New or worsening uremic neuropathy, nausea, pruritus, or altered mental status should trigger immediate nephrology evaluation for possible dialysis initiation (KDIGO) 14.

Cardiovascular Risk Reduction

Lipid Management

• Initiate atorvastatin 20–80 mg daily (or continue if already prescribed) for patients ≥50 years with CKD stage IV to lower cardiovascular risk (KDIGO 2021 lipid guideline, strong recommendation) 15.
• No dose adjustment of atorvastatin is required in CKD stage IV (KDIGO) 16.

Antiplatelet Therapy

• Do not start aspirin for primary cardiovascular prevention in CKD stage IV because bleeding risk outweighs benefit; aspirin is reserved for secondary prevention in patients with established atherosclerotic disease (KDIGO) 17.

Anemia Management

• Continue oral iron (e.g., ferrous fumarate) with monthly hemoglobin monitoring; target transferrin saturation ≥ 20 % and ferritin ≥ 100 ng/mL (KDIGO anemia guideline, moderate evidence) 18.
• If hemoglobin remains < 10 g/dL despite adequate iron stores, initiate erythropoiesis‑stimulating agents (KDIGO) 18.

Immunization Prior to Transplant

• Verify hepatitis B surface antibody titers and revaccinate non‑immune patients before transplantation (KDIGO infection guideline) 17.